Bacteremia and fungemia occurring during antimicrobial prophylaxis with ofloxacin in cancer patients: risk factors, etiology and outcome

Journal of Chemotherapy
S SpánikV Krcméry

Abstract

The authors analyzed 27 breakthrough bacteremias occurring during ofloxacin prophylaxis in afebrile neutropenia over 7 years in 9989 admissions and 979 bacteremic and fungemic episodes in a National Cancer Center in Bratislava, Slovak Republic. The most frequently isolated organisms in breakthrough bacteremias were gram-positive (71.3%), mainly coagulase-negative staphylococci (41.3%), enterococci (9.2%) and Corynebacteria (9.2%), followed by gram-negative rods-Pseudomonas aeruginosa (13.2%) and Stenotrophomonas maltophilia (9.2%). The outcome of breakthrough bacteremias during ofloxacin prophylaxis was not associated with the underlying disease, neutropenia, catheter insertion or resistance, but only with multiple risk factors. A higher failure rate was observed in those patients having a catheter infected with a resistant organism and during neutropenia. No patients with Hickman catheter were included in the study. Patients with mixed breakthrough bacteremia due to gram-negative and gram-positive organisms had higher failure rates than those with monomicrobial bacteremia. Catheter extraction and rapid institution of intravenous antibiotics in combination should be administered in breakthrough bacteremia.

References

Apr 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J A LeccionesT J Walsh
Feb 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G A NoskinJ R Warren
Jan 1, 1994·The Journal of Hospital Infection·V Krcméry, J Trupl
Jan 1, 1994·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·P Y BochudP Francioli
Jun 1, 1994·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·P A Tilley, F J Roberts

❮ Previous
Next ❯

Citations

Jan 1, 1996·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·V KrcmeryE Kukuckova
Jun 25, 2005·Burns : Journal of the International Society for Burn Injuries·Zulal OzkurtM Nuran Akcay
Feb 19, 2013·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Julio Cesar Medina-PresentadoGloria Rieppi
Aug 18, 2009·Enfermedades infecciosas y microbiología clínica·Antoni BassaCarmen Gallegos
Dec 20, 1999·The Journal of Antimicrobial Chemotherapy·K G Kerr

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.